Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ANL011
MIFTS: 35

Anal Canal Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Endocrine diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Anal Canal Carcinoma

About this section

MalaCards integrated aliases for Anal Canal Carcinoma:

Name: Anal Canal Carcinoma 57 12 13 44 15
Carcinoma of Anal Canal 12 73
Anal Canal and Perianal Gland Carcinoma 12
Cancer of the Anal Canal 37

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
anal canal carcinoma:
Inheritance autosomal dominant inheritance


Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Gastrointestinal diseases Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

OMIM 57 105580
Disease Ontology 12 DOID:6126
MeSH 44 C563020
NCIt 50 C7489
SNOMED-CT 68 285310000
MedGen 42 C0563211
KEGG 37 H00044
ICD10 33 C21.1
SNOMED-CT via HPO 69 263681008
UMLS 73 C0563211
Sources

Summaries for Anal Canal Carcinoma

About this section
Disease Ontology : 12 An anal canal cancer that derives from epithelial cells.

MalaCards based summary : Anal Canal Carcinoma, also known as carcinoma of anal canal, is related to anal carcinoma in situ and small cell carcinoma. An important gene associated with Anal Canal Carcinoma is ANC (Anal Canal Carcinoma), and among its related pathways/superpathways are Viral carcinogenesis and Pathways in cancer. The drugs Capecitabine and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include liver, prostate and endothelial, and related phenotypes are anal canal squamous carcinoma and neoplasm

Description from OMIM: 105580
Sources

Related Diseases for Anal Canal Carcinoma

About this section

Diseases related to Anal Canal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 14)
# Related Disease Score Top Affiliating Genes
1 anal carcinoma in situ 11.3
2 small cell carcinoma 9.8
3 suppression of tumorigenicity 12 9.8
4 burns 9.8
5 leukemia 9.8
6 prostatitis 9.8
7 adenocarcinoma 9.8
8 cervical intraepithelial neoplasia 9.6 CDKN2A NME1
9 larynx cancer 9.4 CDKN2A NME1
10 integumentary system cancer 9.4 CDKN2A GLI1
11 nervous system cancer 9.4 CDKN2A GLI1
12 melanoma, uveal 9.2 CDKN2A NME1
13 pancreas adenocarcinoma 9.2 CDKN2A GLI1
14 skin melanoma 9.0 CDKN2A NME1

Graphical network of the top 20 diseases related to Anal Canal Carcinoma:



Diseases related to Anal Canal Carcinoma
Sources

Symptoms & Phenotypes for Anal Canal Carcinoma

About this section

Symptoms via clinical synopsis from OMIM:

57
Oncology:
anal canal squamous carcinoma


Clinical features from OMIM:

105580

Human phenotypes related to Anal Canal Carcinoma:

32
# Description HPO Frequency HPO Source Accession
1 anal canal squamous carcinoma 32 HP:0006763

MGI Mouse Phenotypes related to Anal Canal Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 8.92 CDKN2A GLI1 NME1 NQO1
Sources

Drugs & Therapeutics for Anal Canal Carcinoma

About this section

Drugs for Anal Canal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 24)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
2
Fluorouracil Approved Phase 2 51-21-8 3385
3
Daratumumab Approved Phase 1, Phase 2 945721-28-8
4
nivolumab Approved Phase 1, Phase 2,Phase 2 946414-94-4
5
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
6
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
7
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
8
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
9 Alkylating Agents Phase 2
10 Anti-Bacterial Agents Phase 2
11 Antibiotics, Antitubercular Phase 2
12 Antimetabolites Phase 2
13 Antimetabolites, Antineoplastic Phase 2
14 Immunosuppressive Agents Phase 2
15 Mitomycins Phase 2
16 Nucleic Acid Synthesis Inhibitors Phase 2
17 Antibodies Phase 1, Phase 2,Phase 2
18 Antibodies, Monoclonal Phase 1, Phase 2,Phase 2
19 Immunoglobulins Phase 1, Phase 2,Phase 2
20 Liver Extracts Phase 2
21 Antimitotic Agents Phase 2
22 taxane Phase 2
23 Albumin-Bound Paclitaxel Phase 2
24 Antineoplastic Agents, Phytogenic Phase 2

Interventional clinical trials:

(show all 18)
# Name Status NCT ID Phase Drugs
1 A Phase II Study to Assess Acute Toxicity and Quality of Life of Patients With Carcinoma of the Anal Canal Receiving Chemotherapy and Radiation Using Helical Tomotherapy Unknown status NCT00754078 Phase 2
2 A Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal. Completed NCT01941966 Phase 2 Capecitabine;Mitomycins
3 Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life Recruiting NCT02701088 Phase 2 5Fluorouracile and Mitomycin-C
4 Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection Recruiting NCT02437851 Phase 2
5 An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors Recruiting NCT02488759 Phase 1, Phase 2 Nivolumab;Ipilimumab;BMS-986016;Daratumumab
6 Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases Recruiting NCT02185443 Phase 2
7 Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers Recruiting NCT03403465 Phase 2
8 Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer Recruiting NCT03233711 Phase 2
9 Nivolumab in Treating Patients With Refractory Metastatic Anal Canal Cancer Active, not recruiting NCT02314169 Phase 2
10 Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma Active, not recruiting NCT02402842 Phase 2 Docetaxel, Cisplatin and 5-Fluorouracil
11 Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer Active, not recruiting NCT02560298 Phase 2 Capecitabine;Carboplatin;Cisplatin;Fluorouracil;Paclitaxel
12 Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers Terminated NCT01382745 Phase 2 Nimotuzumab
13 Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal Terminated NCT01843452 Phase 2 MITOMYCIN;CAPECITABINE
14 Interstitial Brachytherapy Boost for Treatment of Anal Canal Cancers, Comparison of Two Dose Rates Completed NCT03465501
15 Chemoradiation and Endothelial Progenitor Cells in Colorectal Cancer Completed NCT00325871
16 Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal Recruiting NCT01845779 Not Applicable DCF regimen
17 Individual Following in Anal Cancer With PET/CT Recruiting NCT02697084
18 Medico-economic Evaluation Comparing Intensity-Modulated Radiation Therapy (IMRT) Performed by Helical Tomotherapy and Dynamic Arc Therapy in Prostate, Cervical and Anal Canal Cancers Active, not recruiting NCT01325961 Not Applicable

Search NIH Clinical Center for Anal Canal Carcinoma

Cochrane evidence based reviews: anal canal carcinoma

Sources

Genetic Tests for Anal Canal Carcinoma

About this section
Sources

Anatomical Context for Anal Canal Carcinoma

About this section

MalaCards organs/tissues related to Anal Canal Carcinoma:

41
Liver, Prostate, Endothelial, Skin
Sources

Publications for Anal Canal Carcinoma

About this section

Articles related to Anal Canal Carcinoma:

(show top 50) (show all 69)
# Title Authors Year
1
Association of Interim FDG-PET Imaging During Chemoradiation for Squamous Anal Canal Carcinoma With Recurrence. ( 29891206 )
2018
2
Anal Canal Carcinoma in a Child With Disorders of Sex Development. ( 27037640 )
2016
3
Proteomic signatures reveal a dualistic and clinically relevant classification of anal canal carcinoma. ( 27976366 )
2016
4
Shifting paradigm in the management of anal canal carcinoma. ( 25432583 )
2015
5
Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities. ( 25903798 )
2015
6
Locally advanced anal canal carcinoma: is the addition of cetuximab the answer? ( 25976929 )
2015
7
Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. ( 24243447 )
2014
8
Management of persistent anal canal carcinoma after combined-modality therapy: a clinical review. ( 24472223 )
2014
9
Reply to phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. ( 24243421 )
2014
10
Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. ( 23674135 )
2013
11
Benefit of MRI scanning in the pretreatment assessment of anal canal carcinoma. ( 24674573 )
2013
12
Changing patterns of anal canal carcinoma in the United States. ( 23509304 )
2013
13
Light microscopic observation on phagocytosis of Candida spp. blastospores by Trichomonas vaginalis in a patient with anal canal carcinoma. ( 21395883 )
2012
14
Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. ( 22529257 )
2012
15
Chemotherapy in the treatment of anal canal carcinoma. ( 22658644 )
2012
16
Endobronchial metastases of anal canal carcinoma. ( 22055765 )
2012
17
Mitomycin-C- or cisplatin-based chemoradiotherapy for anal canal carcinoma: long-term results. ( 20472349 )
2011
18
Anal canal carcinoma treatment results: the experience of a single institution. ( 21403412 )
2011
19
The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series. ( 21772841 )
2011
20
Results of salvage abdominoperineal resection after failed chemoradiation therapy for epidermoid anal canal carcinoma: Retrospective analysis at a single institution. ( 22331724 )
2011
21
Twenty-year experience in the management of squamous cell anal canal carcinoma with interstitial brachytherapy. ( 21775274 )
2011
22
Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma. ( 20492729 )
2010
23
Post burn Marjolin's ulcer in the natal cleft mimicking anal canal carcinoma: a rare site. ( 21160444 )
2010
24
Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. ( 19399614 )
2010
25
Conformal external beam radiotherapy in the treatment of anal canal carcinoma: a retrospective study of a genital organ sparing technique. ( 19695047 )
2009
26
Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281). ( 18490648 )
2008
27
Radiotherapy and chemotherapy in the conservative treatment of anal canal carcinoma. ( 18505075 )
2008
28
Radiochemotherapy of locally advanced anal canal carcinoma: prospective assessment of early impact on the quality of life (randomized trial ACCORD 03). ( 18191265 )
2008
29
Chemotherapy and radiotherapy for anal canal carcinoma. ( 18812528 )
2008
30
The aspects of angiogenesis in anal canal carcinomas compared with that in colorectal carcinomas. ( 18060184 )
2007
31
Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans. ( 18005443 )
2007
32
External beam radiotherapy plus brachytherapy boost in treatment of anal canal carcinoma. ( 17988027 )
2007
33
Anal canal carcinoma with Pagetoid spread: report of a case. ( 16794808 )
2006
34
Treatment of squamous cell anal canal carcinoma (SCACC) with pulsed dose rate brachytherapy: a retrospective study. ( 16631268 )
2006
35
Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. ( 15752894 )
2005
36
Epidermal growth factor receptor expression in anal canal carcinoma. ( 15923158 )
2005
37
Anal canal carcinoma: early-stage tumors < or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy. ( 15890590 )
2005
38
Contribution of conformal therapy in the treatment of anal canal carcinoma with combined chemotherapy and radiotherapy: results of a phase II study. ( 12788191 )
2003
39
Intracavitary afterloading boost in anal canal carcinoma. Results, function and quality of life. ( 11398611 )
2001
40
The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy. ( 11395235 )
2001
41
Prognostic impact of CD31 antigen expression in anal canal carcinoma. ( 11677963 )
2001
42
Analysis of a follow-up program for anal canal carcinoma. ( 11484975 )
2001
43
Immunohistochemical assessment of Ki-67 as prognostic cellular proliferation marker in anal canal carcinoma. ( 11277325 )
2000
44
An unusual late radiotherapy-related complication requiring surgery in anal canal carcinoma. ( 10914830 )
2000
45
Patterns of recurrence in anal canal carcinoma. ( 10982516 )
2000
46
nm23-H1 protein expression in anal canal carcinoma: does it correlate with prognosis? ( 10914829 )
2000
47
Treatment of squamous cell anal canal carcinoma with pulsed dose rate brachytherapy. Feasibility study of a French cooperative group. ( 10435803 )
1999
48
Human papillomavirus infection and p53 nuclear overexpression in anal canal carcinoma. ( 10374676 )
1999
49
Correlation between nm23-H1 overexpression and clinicopathological variables in human anal canal carcinoma. ( 10523705 )
1999
50
Sphincter preservation with chemoradiation in anal canal carcinoma: abdominoperineal resection in selected cases? ( 9559628 )
1998
Sources

Variations for Anal Canal Carcinoma

About this section
Sources

Expression for Anal Canal Carcinoma

About this section
Search GEO for disease gene expression data for Anal Canal Carcinoma.
Sources

Pathways for Anal Canal Carcinoma

About this section

Pathways related to Anal Canal Carcinoma according to KEGG:

37
# Name Kegg Source Accession
1 Viral carcinogenesis hsa05203

Pathways related to Anal Canal Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Pathways in cancer 37
11.52 CDKN2A GLI1 NQO1
Sources

GO Terms for Anal Canal Carcinoma

About this section
Sources

Sources for Anal Canal Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....